Domain Therapeutics
Founded 2008 · 36 employees on LinkedIn · 11 known investors
Find your way into Domain Therapeutics
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation. The company leverages a proprietary drug discovery platform and two decades of expertise to create first-in-class and best-in-class drug candidates.
Investors · 11
3B Future Health FundMonaco · $12M
CTI Life Sciences Fund L.P.Montréal
adMare BioInnovationsreportedVancouver
Panacea Venturereported · 2 sourcesSingapore
Seventure Partnersreported · 2 sourcesParis
Also in the syndicate · 6
CTI Life SciencesleadOmnesSchroders CapitalTheodorusTurenne CapitalViva BioInnovator
Funding
SEC filings, press & company announcements- Undisclosed amountseries AMay 2022
3B Future Health Fund (lead), CTI Life Sciences (lead), Panacea Venture (lead), adMare BioInnovations, Omnes, Schroders Capital, Seventure Partners, Theodorus, Turenne Capital, Viva BioInnovator
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Domain Therapeutics do?
- Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation. The company leverages a proprietary drug discovery platform and two decades of expertise to create first-in-class and best-in-class drug candidates.
- Who are Domain Therapeutics's investors?
- Domain Therapeutics's investors include 3B Future Health Fund, CTI Life Sciences Fund L.P., adMare BioInnovations, Panacea Venture, Seventure Partners.